CurveBeam AI Lifts Quarterly Receipts, Advances China Tie-Up and FDA BMD Push

Curvebeam AI Ltd. ( (AU:CVB) ) just unveiled an announcement.

CurveBeam AI reported five device purchase orders in the December 2025 quarter, all from the US, alongside customer receipts of A$2.4 million, a 75% increase on the prior quarter, leaving A$4.8 million in purchase orders and receivables carried into Q3 and reflecting a two-to-six-month revenue recognition cycle from order to installation and payment. Operationally, the company progressed its commercialisation partnership with WEGO Orthopaedics in China, advancing regulatory engagement and promotional activity for the HiRise system, triggered a A$4.0 million milestone equity investment from WEGO, submitted an FDA 510(k) application for its MDCT BMD software module targeting mid-2026 clearance, and took a key step toward validating HiRise compatibility with a major robotic surgery system—developments that, if executed as planned, could broaden its addressable market, strengthen its international footprint and support future revenue growth.

The most recent analyst rating on (AU:CVB) stock is a Hold with a A$0.15 price target. To see the full list of analyst forecasts on Curvebeam AI Ltd. stock, see the AU:CVB Stock Forecast page.

More about Curvebeam AI Ltd.

CurveBeam AI Limited is an ASX-listed developer of point-of-care specialised medical CT imaging equipment and AI-enabled, SaaS-based clinical assessment solutions, with operations in Melbourne and Hatfield, Pennsylvania. Its product suite includes the HiRise weight-bearing CT system and LineUp devices, and it is increasingly focusing on advanced imaging applications such as bone mineral density (BMD) analysis for orthopaedic and acute care markets, particularly in the US and China.

Average Trading Volume: 1,609,624

Technical Sentiment Signal: Sell

Current Market Cap: A$37.9M

See more insights into CVB stock on TipRanks’ Stock Analysis page.